ÌìÃÀÓ°Ôº

°ä²¹°ù°ù¾±Ã¨°ù±ð²õEspace presseCOVID-19
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Liver Fibrosis Assays 
  5. ELF Test Educational Videos

ELF Test Educational Videos

Dr. Arun Sanyal
Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

Virginia Commonwealth University

How are you Testing your NASH Patients?

Ìý01.07.22

Why risk-stratification in NASH patients is so important

Medscape Education Diabetes & Endocrinology

Implementing Best Practices in Fatty Liver Disease

Ìý23.06.22

In this Medscape activity, Dr. Cusi summarizes key points on the diagnosis and treatment strategies of NAFLD

Dr. Jörn Schattenberg
Professor of Medicine and Director
Metabolic Liver Research Program

University Medical Center Mainz, Germany

Redefining the NAFLD/NASH Referral Pathway: A Hepatologist's Perspective

Ìý10.12.21

Utility of noninvasive tests such as the ELF Test in the patient referral pathway

Dr. Manuel Romero-Gómez
Professor of Medicine
UCM Digestive Diseases

Virgen del Rocío University Hospital; SeLiver group at Institute of Biomedicie of Seville (IBIS), University of Seville, Sevilla, Spain

Multidisciplinary Approach in the NAFLD/NASH Patient Care Pathway

Ìý10.12.21

An understanding of NAFLD/NASH across specialties and why the use of noninvasive tests are needed. 

Dr. Scott D. Isaacs
Dr. Scott D. Isaacs, MD, FACP, FACE
Endocrinologist and Obesity Medicine Specialist

Atlanta Endocrine Associates, Atlanta, Georgia

NASH Prevalence in Type 2 Diabetes Patients and Use of Noninvasive Tests

Ìý10.12.21

How do endocrinologists manage type 2 diabetes patients with NAFLD/NASH?

Professor Jerome Boursier
Prof. Jérôme Boursier, MD, PhD
Faculty of Medicine

University of Angers, Angers, France

Noninvasive Liver Fibrosis Testing Starts in the Primary Care Setting

Ìý10.12.21

Turning the tide against nonalcoholic fatty liver disease (NAFLD)

Dr.Mazen Noureddin
Director of Fatty Liver Program

Cedars Sinai, Los Angeles, CA

Noninvasive Prognostic Tests in NASH Patient Management


Ìý10.12.21

How noninvasive tests such as the ELFâ„¢ Test are changing the field.

Dr. Zobair M. Younossi in his office
Dr. Zobair M. Younossi
Professor and Chairman of Medicine
Inova Fairfax Medical Campus, Virginia

The U.S. Economic Burden of Nonalcoholic Steatohepatitis (NASH)

Ìý10.12.21

Noninvasive tests provide an important tool to help reduce healthcare costs. 

Dr. Ankur Srivastava
Dr. Ankur Srivastava
Consultant Gastroenterologist and Hepatologist
Southmead Hospital, North Bristol Trust

A Novel Two-step Pathway to Detect Liver Cirrhosis Earlier

Ìý21.08.19

Non-invasive tests can help reduce unnecessary referrals in patients with NAFLD

Detect Liver Cirrhosis Earlier
Addressing the Rising Prevalence of Non-alcoholic Fatty Liver Disease
Dr. Zobair M. Younossi
Professor & Chairman of Medicine,
Inova Fairfax Hospital, Virginia

Addressing the Rising Prevalence of Non-alcoholic Fatty Liver Disease

Ìý16.08.19

Prevalence of NAFLD in patients with both type 2 diabetes and obesity is over 75%

Rising Prevalence NAFLD

The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.